Wednesday, October 14, 2026

Monetary Policy

44 articles

Bank of England Rate Cuts Hit 84% Probability for March as Global Easing Cycle Accelerates

Bank of England Rate Cuts Hit 84% Probability for March as Global Easing Cycle Accelerates

Markets now price 84% odds for Bank of England rate cuts in March 2026 as inflation cools across major economies. Central banks are executing coordinated easing with two 25-basis-point BoE cuts expected by autumn, while the Federal Reserve faces leadership transition uncertainty as Powell and Miran terms expire.

ViaNews Editorial Team (Finance)•
Central Banks Split on 2026 Rates as ECB Eyes Hikes, Indonesia Signals More Cuts

Central Banks Split on 2026 Rates as ECB Eyes Hikes, Indonesia Signals More Cuts

Major central banks are taking divergent paths in early 2026, with the ECB's Isabel Schnabel floating potential rate hikes while Bank Indonesia's Perry Warjiyo signals room for further cuts. The policy splits are driving currency volatility as investors reposition portfolios across regions with widening rate differentials.

ViaNews Editorial Team (Finance)•
Fed Signals Prolonged Rate Pause as Bar for Further Cuts Rises Sharply

Fed Signals Prolonged Rate Pause as Bar for Further Cuts Rises Sharply

The Federal Reserve has effectively halted its easing cycle, with Chair Jerome Powell and multiple policymakers signaling that interest rates are near neutral and that further cuts require a substantially higher bar. Markets have repriced expectations accordingly, with traders now assigning just a 51% probability of a single 25-basis-point cut by June 2026. The Fed's cautious stance reflects a balancing act between residual inflation concerns and a resilient economy buoyed by consumer spending a

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com